Atea Pharmaceuticals (AVIR) vs Galectin Therapeutics (GALT)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Atea Pharmaceuticals (AVIR) has outperformed Galectin Therapeutics (GALT) over the past year, gaining 66.3% versus a loss of 23.2%. Over five years, GALT leads with a +8.0% price change compared with -86.9% for AVIR. Atea Pharmaceuticals is the larger company by market cap ($413.5 million vs $367.1 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AVIR | GALT |
|---|---|---|
| Share price | $5.16 | $3.64 |
| Market cap | $413.46M | $367.09M |
| 1-day change | +2.89% | +0.55% |
| YTD return | +44.40% | -12.50% |
| 1-year return | +66.29% | -23.21% |
| 5-year return | -86.88% | +8.01% |
| EPS (TTM) | $-2.09 | $-0.43 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.45 | $7.13 |
| 52-week low | $2.87 | $2.03 |
| Distance from 52-week high | -20.08% | -48.95% |
| Analyst consensus | none | none |
| Avg. price target upside | +82.74% | +202.20% |
| Average volume | 298.98K | 385.71K |
| Shares outstanding | 80.20M | 100.85M |
| Employees | 55 | 9 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- AVIR has outperformed GALT by 89.5 percentage points over the past year.
About Atea Pharmaceuticals
AVIR stock →Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes oral antiviral therapeutics for patients with serious viral infections. Its lead product candidate is the regimen of bemnifosbuvir, a nucleotide NS5B inhibitor, and ruzasvir, an NS5A inhibitor, which is in Phase 3 clinical trial for the treatment of hepatitis C virus (HCV).
Health Care · Biotechnology: Pharmaceutical Preparations · 55 employees
About Galectin Therapeutics
GALT stock →Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in drug development to create new therapies for fibrotic disease and cancer. The company's lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in a Phase 2 clinical study in MASH patients with advanced fibrosis and a second Phase 2b clinical trial in MASH patients with compensated cirrhosis and portal hypertension.
Health Care · Biotechnology: Pharmaceutical Preparations · 9 employees
AVIR vs GALT FAQ
Which is bigger, Atea Pharmaceuticals or Galectin Therapeutics?
Atea Pharmaceuticals (AVIR) is larger, with a market capitalization of $413.46M compared with $367.09M for Galectin Therapeutics (GALT).
Which stock has performed better over the past year, AVIR or GALT?
AVIR returned +66.29% over the past 12 months, compared with -23.21% for GALT (price return, excluding dividends). Past performance does not predict future results.
Are Atea Pharmaceuticals and Galectin Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.